Traders bought shares of Allergan PLC (NYSE:AGN) on weakness during trading on Thursday. $417.52 million flowed into the stock on the tick-up and $363.46 million flowed out of the stock on the tick-down, for a money net flow of $54.06 million into the stock. Of all equities tracked, Allergan PLC had the 2nd highest net in-flow for the day. Allergan PLC traded down ($6.96) for the day and closed at $236.31

AGN has been the subject of several research analyst reports. Mizuho reissued a “neutral” rating and issued a $232.00 price objective (down from $250.00) on shares of Allergan PLC in a research report on Tuesday, May 10th. Piper Jaffray Cos. reissued a “hold” rating and issued a $236.00 price objective on shares of Allergan PLC in a research report on Saturday, June 18th. Credit Suisse Group AG set a $322.00 price objective on Allergan PLC and gave the stock a “hold” rating in a research report on Wednesday, August 3rd. Vetr lowered Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $275.94 price objective for the company. in a research report on Thursday, June 2nd. Finally, Leerink Swann reissued a “buy” rating on shares of Allergan PLC in a research report on Thursday, June 30th. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $309.13.

The company has a 50 day moving average price of $248.71 and a 200-day moving average price of $248.84. The company has a market cap of $94.21 billion and a P/E ratio of 22.65.

Allergan PLC (NYSE:AGN) last announced its earnings results on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.34 by $0.01. The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $4.10 billion. Allergan PLC’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period in the prior year, the business posted $4.41 EPS. Equities analysts expect that Allergan PLC will post $14.00 earnings per share for the current fiscal year.

In other Allergan PLC news, CFO Maria Teresa Hilado bought 661 shares of the firm’s stock in a transaction on Thursday, June 2nd. The stock was acquired at an average price of $241.57 per share, with a total value of $159,677.77. Following the completion of the purchase, the chief financial officer now owns 11,957 shares of the company’s stock, valued at $2,888,452.49. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Other institutional investors have made changes to their positions in the company. Rail Splitter Capital Management LLC increased its position in shares of Allergan PLC by 39.4% in the fourth quarter. Rail Splitter Capital Management LLC now owns 51,574 shares of the company’s stock worth $16,117,000 after buying an additional 14,565 shares in the last quarter. Schroder Investment Management Group increased its position in shares of Allergan PLC by 5.9% in the fourth quarter. Schroder Investment Management Group now owns 102,742 shares of the company’s stock worth $32,107,000 after buying an additional 5,700 shares in the last quarter. American International Group Inc. increased its position in shares of Allergan PLC by 1.5% in the fourth quarter. American International Group Inc. now owns 164,589 shares of the company’s stock worth $51,435,000 after buying an additional 2,511 shares in the last quarter. State of Tennessee Treasury Department increased its position in shares of Allergan PLC by 135.7% in the fourth quarter. State of Tennessee Treasury Department now owns 466,141 shares of the company’s stock worth $145,669,000 after buying an additional 268,357 shares in the last quarter. Finally, Eaton Vance Management increased its position in shares of Allergan PLC by 276.7% in the fourth quarter. Eaton Vance Management now owns 793,555 shares of the company’s stock worth $247,986,000 after buying an additional 582,890 shares in the last quarter.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.